Literature DB >> 25523378

Anterior retropharyngeal approach to C1 for percutaneous vertebroplasty under C-arm fluoroscopy.

Jun-Song Yang1, Lei Chu2, Fu-Tao Xiao2, Dong-Jie Zhang2, Yang Wang2, Liang Chen2, Zhen-Yong Ke2, Ding-Jun Hao3, Zhong-Liang Deng4.   

Abstract

BACKGROUND CONTEXT: Percutaneous vertebroplasty (PVP) has proven to be a valuable palliative treatment option for patients with medically refractory painful osteolytic metastases of the spine. Percutaneous vertebroplasty of the atlas has been reported in only seven articles and has been performed with different techniques and approaches.
PURPOSE: To describe the technique we used to perform PVP of a lytic lesion of the lateral mass of C1 via anterior retropharyngeal approach guided by C-arm fluoroscopy. STUDY
DESIGN: A technical report. PATIENT SAMPLE: It included a 75-year-old man with known metastatic lung carcinoma and incapacitating right suboccipital and neck pain refractory to conventional medical treatment. Radiologic evaluation showed revealed osteolytic destruction of C1 and C2, mainly invading the right lateral mass of C1 and the vertebral body of C2. OUTCOME MEASURES: The right suboccipital and neck pain was measured using the visual analog scale (VAS).
METHODS: Under C-arm fluoroscopy, a novel anterior retropharyngeal approach, through the vertebral body of C2 into the metastatic osteolytic vertebral lesion of C1, was performed to achieve the PVP in C1 followed by a PVP in C2.
RESULTS: Immediately after the operation, the patient reported substantial pain relief (from VAS 9/10 preoperatively to 3/10). At 12 hours postoperatively, the range of motion was also improved. There were no surgery-related complications. The immediately postoperative cervical plain film and computed tomography scan showed adequate filling of the osteolytic lesion without the obvious leakage of bone cement. Clinical follow-up at 3 months revealed that this pain condition was improved and maintained (VAS 1/10).
CONCLUSIONS: When the transoral approach is unsuitable or contraindicated, the anterior retropharyngeal approach could be an efficacious alternative in selected patients with C1 metastasis, providing adequate filling of bone cement and significant pain relief. Based on our preliminary exploration, only assisted by C-arm fluoroscopy, this approach is feasible to achieve PVP in C1 under local anesthesia and intravenous analgesia. Nevertheless, when considering the substantial potential risks, this technically challenging procedure should be performed by experienced operators.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anterior; Atlas/C1; Fluoroscopy; Metastasis; Percutaneous; Retropharyngeal approach; Vertebroplasty

Mesh:

Substances:

Year:  2014        PMID: 25523378     DOI: 10.1016/j.spinee.2014.12.014

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  4 in total

1.  Percutaneous Image-Guided Anterior Screw Fixation of the Odontoid Process.

Authors:  Pierre-Alexis Autrusseau; Damien Heidelberg; Nicolas Stacoffe; Danoob Dalili; Roberto Luigi Cazzato; Guillaume Koch; Afshin Gangi; Julien Garnon
Journal:  Cardiovasc Intervent Radiol       Date:  2021-01-03       Impact factor: 2.740

2.  Percutaneous Vertebroplasty Relieves Pain in Cervical Spine Metastases.

Authors:  Li Bao; Pu Jia; Jinjun Li; Hao Chen; Yipeng Dong; Fei Feng; He Yang; Mengmeng Chen; Hai Tang
Journal:  Pain Res Manag       Date:  2017-01-23       Impact factor: 3.037

3.  Percutaneous Vertebroplasty for C1 Osteolytic Lesions via Lateral Approach Under Fluoroscopic Guidance.

Authors:  Yue Yang; Qinghua Tian; Dan Wang; Fei Yi; Hongmei Song; Wenbin Li; Chungen Wu
Journal:  J Pain Res       Date:  2021-07-13       Impact factor: 3.133

4.  Posterior Percutaneous Transpedicular Endoscopic Approach for Treating Single-Segment Cervical Myelopathy.

Authors:  Ke-Xiao Yu; Wei-Zhong Lu; Chang-Ming Xiao; Lei Chu; Rui Deng; Liang Chen; Zhong-Liang Deng
Journal:  Biomed Res Int       Date:  2020-10-22       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.